Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

CCRT improves survival in advanced NPC, induction chemo shows potential benefit

Roshini Claire Anthony
01 Nov 2019

Concurrent chemoradiotherapy (CCRT) appeared to improve survival rates in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), according to a systematic review and meta-analysis, with a potential benefit noted with the addition of induction chemotherapy.

“This updated and comprehensive meta-analysis … confirmed the benefits associated with the addition of chemotherapy to radiotherapy, including significant and clinically relevant improvements in all [survival] outcomes [assessed] … Survival benefit was also associated with the addition of induction chemotherapy but not adjuvant chemotherapy to CCRT,” said the researchers.

The researchers reviewed 28 randomized clinical trials (RCTs) comprising 8,036 treatment-naïve patients with non-distant metastatic NPC (median age 46.5 years, 73.1 percent male) who had received radiotherapy with chemotherapy (at different time points) or radiotherapy alone. Trial sequential analysis was used to confirm the outcomes. Patients were followed up for a median 30–128.4 months. Seventeen of the trials were determined as having a low risk of bias.

Overall, the addition of chemotherapy to radiotherapy led to a significant improvement in overall survival (OS; hazard ratio [HR], 0.76, 95 percent confidence interval [CI], 0.69–0.84), progression-free survival (PFS; HR, 0.72, 95 percent CI, 0.66–0.79), distant metastasis-free survival (DMFS; HR, 0.68, 95 percent CI, 0.60–0.75), and locoregional recurrence-free survival (LRFS; HR, 0.71, 95 percent CI, 0.63–0.79). [JAMA Network Open 2019:2:e1913619]

Between-trial heterogeneity was determined as low to moderate for OS and PFS (p=0.03 and p=0.02, respectively), and nonsignificant for DMFS and LRFS (p=0.14 and p=0.50, respectively).

The survival improvements appeared specific to the addition of induction chemotherapy (OS: HR, 0.84, 95 percent CI, 0.74–0.95; PFS: HR, 0.73, 95 percent CI, 0.64–0.84; DMFS: HR, 0.67, 95 percent CI, 0.58–0.77; LRFS: HR, 0.74, 95 percent CI, 0.61–0.86) or CCRT (OS: HR, 0.66, 95 percent CI, 0.51–0.85; PFS: HR, 0.73, 95 percent CI, 0.57–0.93; DMFS: HR, 0.69, 95 percent CI, 0.48–0.85; LRFS: HR, 0.70, 95 percent CI, 0.53–0.98).

According to the researchers, RCTs examining the addition of induction or adjuvant chemotherapy to radiotherapy in NPC have produced contrasting findings, leading to controversy regarding the added value of its use.

In the present study, subgroup analysis demonstrated greater OS, PFS, DMFS, and LRFS with induction chemotherapy plus radiotherapy compared with radiotherapy alone (HR, 0.87, 0.73, 0.71, and 0.75, respectively) or with induction chemotherapy plus CCRT vs CCRT (HR, 0.81, 0.73, 0.64, and 0.73, respectively), though this was affected by factors such as study design, tumour stage, and bias.

“[M]ulticentre trials with sample sizes [>250], survival rate of [5 years], median follow-up time [>60 months], and low bias have provided data suggestive of a benefit from adding [induction chemotherapy] to the treatment regimen for locoregionally advanced NPC,” the researchers noted, suggesting that these disparities may have been behind the conflicting findings in previous studies.

Contrastingly, the addition of adjuvant chemotherapy did not result in additional survival advantage (OS: HR, 0.98; PFS: 0.86; DMFS: HR, 0.84; LRFS: HR, 0.80), though there was a significant survival improvement when adjuvant chemotherapy was added to CCRT vs radiotherapy alone (OS: HR, 0.63; PFS: HR, 0.64; DMFS: HR, 0.62; LRFS: HR, 0.61).

The most common toxicities experienced by chemoradiotherapy recipients were haematologic- and digestive-related, with acute toxicity most common in patients on CCRT plus induction or adjuvant chemotherapy.

“The results of this study support the use of CCRT as the standard treatment for locoregionally advanced NPC,” said the researchers.

“The addition of induction chemotherapy instead of adjuvant chemotherapy to CCRT was associated with an additional survival benefit,” they continued, cautioning that adding induction chemotherapy may not suit all patients and methods must be undertaken to select those who would derive the most benefit.

Additionally, the lack of effect noted with adjuvant chemotherapy could be due to the small number of trials and as such, more RCTs are needed to assess its impact in NPC, they said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]